Australia's most trusted
source of pharma news
Posted 19 June 2026 AM
A massive 18 new indication applications were accepted for evaluation between March and April, with new cancer labels making up more than half of the applications – and MSD leading the charge.
Two of MSD’s four applications cover the combination treatment of Keytruda and Welireg for the adjuvant treatment of adult patients with renal cell carcinoma with a clear cell component at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.